Both aducanumab and lecanemab — Eisai and Biogen’s Alzheimer’s drugs — are not only targeted at reducing the clumped beta-amyloid that has mystified and encouraged researchers for decades, using the same FDA accelerated approval pathway, and could also put a serious dent in Medicare’s budget.
Last night’s big unveiling of…
